Filters

Pp-195 manufacturers

Filters

None products found

pp-195

Solution for infusion

Dossier type
CTD
Dossier status
Under development
Country of origin
Israel
GMP approvals
Israel
Comments
Indication: Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Clinical stage: Phase 2 — ongoing (combination with pembrolizumab) Modality: Small molecule (first-in-class dual signalling inhibitor) Mechanism / Target: First-in-class dual inhibitor of IRS-1/IRS-2 (insulin receptor substrate 1/2) and STAT3 signalling pathways; disrupts two key oncogenic survival cascades simultaneously; reduces resistance to checkpoint inhibitors Route / form: IV infusion Differentiation: First-in-class IRS1/2+STAT3 inhibitor; novel small molecule targeting two distinct tumour survival pathways simultaneously; Phase 2 in SCCHN with combination immunotherapy;
Manufacturer #39334
Israeli clinical-stage company developing Rx first-in-class cancer therapeutics targeting the tumor microenvironment to overcome drug resistance and immune evasion. Biologic pipeline focuses on oncology with combination approaches designed to improve outcomes for solid tumor patients. Publicly listed on international and domestic exchanges with ongoing global clinical trials.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.